Should Value Investors Buy DaVita (DVA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $155.06, denoting a +1.33% change from the preceding trading day.
DaVita Stock Gains 40.1% Year to Date: What's Behind the Rally?
Strength in kidney care services and expansion into international markets raise optimism for DVA stock.
DaVita: Better Results Than Fresenius, But A 'Hold' Due To Valuation
Despite operational success and growth potential, I rate DaVita Inc. a “Hold” due to its high debt, lack of dividend, and current overvaluation. DaVita excels in dialysis services but faces significant risks from debt servicing costs, macroeconomic factors, and potential policy changes. The company's recent financial performance, including a decline in net income and increased debt costs, underscores my conservative valuation approach.
Why DaVita Stock Withered on Wednesday
The company's profitability is going in the wrong direction for many investors.
DaVita Stock Declines After Q3 Earnings Miss Estimates, Margins Up
DVA's robust Dialysis patient service revenues drives its third-quarter performance.
DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript
DaVita Inc. (NYSE:DVA ) Q3 2024 Earnings Conference Call October 29, 2024 5:00 PM ET Company Participants Nic Eliason - Group Vice President, Investor Relations Javier Rodriguez - Chief Executive Officer Joel Ackerman - Chief Financial Officer Conference Call Participants Andrew Mok - Barclays AJ Rice - UBS Pito Chickering - Deutsche Bank Lisa Clive - Bernstein Joanna Gajuk - Bank of America Ryan Langston - TD Cowen Justin Lake - Wolfe Research Operator Good evening. My name is Michelle and I will be your conference facilitator today.
DaVita HealthCare (DVA) Q3 Earnings Miss Estimates
DaVita HealthCare (DVA) came out with quarterly earnings of $2.59 per share, missing the Zacks Consensus Estimate of $2.76 per share. This compares to earnings of $2.85 per share a year ago.
DaVita misses third-quarter profit estimates on higher costs
DaVita reported third-quarter profit that missed Wall Street estimates on Tuesday, hurt by high patient care costs.
6 Stocks Dominate Market's 'Best 6 Months' — Starting This Week
If you had to choose the best time to invest in the S&P 500 — it's the six months starting in November.
DVA Q3 Estimates Unchanged Before Earnings: How to Play the Stock?
Improvement in RPT is likely to have boosted DaVita's top line in the third quarter.
DaVita HealthCare (DVA) Increases Despite Market Slip: Here's What You Need to Know
DaVita HealthCare (DVA) concluded the recent trading session at $163.16, signifying a +1% move from its prior day's close.
